A preliminary investigation into the action of anagrelide: Thrombopoietin-c-Mpl receptor interactions

Experimental Hematology

Volumn 34, Issue 1, 2006, Pages 87-96

  McCarty, John M ^a,c   Melone, Pamela D ^a   Simanis, Juris P ^b   Kanamori, David ^b   Dessypris, Emmanuel N ^b   Warshamana Greene, G Sakuntala ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENYL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM; ANAGRELIDE; C MPL RECEPTOR; FIBRINOGEN RECEPTOR; INTERLEUKIN 3; PHOSPHOTYROSINE; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STEM CELL; WESTERN BLOTTING;

ANTIGENS, CD34; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-3; MODELS, BIOLOGICAL; PHOSPHOTYROSINE; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEIN IIB; PLOIDIES; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RECEPTORS, CYTOKINE; RECEPTORS, THROMBOPOIETIN; THROMBOPOIETIN;

ANIMALIA; MURINAE;

EID: 30344487584     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2005.09.009     Document Type: Article

References (32)

1. A. Tomer Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia Blood 99 2002 1602 1609
2. D.C. Smith, W.P. Vaughan, P.R. Gwilt, and D.L. Trump A phase I trial of high-dose continuous-infusion hydroxyurea Cancer Chemother Pharmacol 33 1993 139 143
3. J.E. Kolitz, S.J. Kempin, and A. Schluger A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia Semin Oncol 19 1992 27 33
4. Anagrelide Study Group Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group Am J Med 92 1992 69 76
5. M.N. Silverstein, R.M. Petitt, L.A. Solberg Jr., J.S. Fleming, R.C. Knight, and L.P. Schacter Anagrelide: a new drug for treating thrombocytosis N Engl J Med 318 1998 1292 1294
6. C.L. Balduini, G. Bertolino, P. Noris, and E. Ascari Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders Haematologica 77 1992 40 43
7. E.M. Mazur, A.G. Rosmarin, P.A. Sohl, J.L. Newton, and A. Narendran Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans Blood 79 1992 1931 1937
8. X.Y. Zhao, J.L. Cai, W.L. Dai, W.G. Zhou, C.B. Li, and S.Y. Zhao [Cloning of a full length cDNA of human thrombopoietin receptor c-Mpl and construction of engineered cells that stably express c-mpl] Sheng Wu Gong Cheng Xue Bao 16 2000 320 323
9. Y. Fan, T. Gao, Y. Ye, and B. Tien Cloning and sequencing of human thrombopoietin cDNA Chin J Biotechnol 13 1997 219 223
10. S. Lok, K. Kaushansky, and R.D. Holly Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo Nature 369 1994 565 568
11. N. Banu, J.F. Wang, B. Deng, J.E. Groopman, and H. Avraham Modulation of megakaryocytopoiesis by thrombopoietin: the c-Mpl ligand Blood 86 1995 1331 1338
12. K. Kaushansky, V.C. Broudy, and N. Lin Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development Proc Natl Acad Sci U S A 92 1995 3234 3238
13. K. Kaushansky Etiology of the myeloproliferative disorders: the role of thrombopoietin Semin Hematol 40 2003 6 9
14. A.L. Taskin, K. Cohen-Solal, and J.P. Le Couedic Myelofibrosis: experimental models and human studies Stem Cells 16 suppl 1998 155 164
15. M. Griesshammer, A. Hornkohl, and J.L. Nichol High levels of thrombopoietin in sera of patients with essential thrombocythemia: cause or consequence of abnormal platelet production? Ann Hematol 77 1998 211 215
16. J. Li, Y. Xia, and D.J. Kuter The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia Br J Haematol 111 2000 943 953
17. A.R. Moliterno, W.D. Hankins, and J.L. Spivak Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera N Engl J Med 338 1998 572 580
18. A.R. Moliterno, K.E. Siebel, A.Y. Sun, W.D. Hankins, and J.L. Spivak A novel thrombopoietin signaling defect in polycythemia vera platelets Stem Cells 16 suppl 2 1998 185 192
19. J.G. Drachman, J.D. Griffin, and K. Kaushansky The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl J Biol Chem 270 1995 4979 4982
20. R. Palacios, and M. Steinmetz Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo Cell 41 1985 727 734
21. G.C. Avanzi, M.F. Brizzi, and J. Giannotti M-07e human leukemic factor-dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSF and IL-3 J Cell Physiol 145 1990 458 464
22. L.C. Strauss, T.M. Trischmann, S.D. Rowley, J.M. Wiley, and C.I. Civin Selection of normal human hematopoietic stem cells for bone marrow transplantation using immunomagnetic microspheres and CD34 antibody Am J Pediatr Hematol Oncol 13 1991 217 221
23. J. Brandt, E.F. Srour, K. van Besien, R.A. Briddell, and R. Hoffman Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow J Clin Invest 86 1990 932 941
24. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 1983 55 63
25. Y. Miyakawa, P. Rojnuckarin, T. Habib, and K. Kaushansky Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes J Biol Chem 276 2001 2494 2502
26. P. Rojnuckarin, J.G. Drachman, and K. Kaushansky Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis Blood 94 1999 1273 1282
27. H.S. Gilbert Historical perspective on the treatment of essential thrombocythemia and polycythemia vera Semin Hematol 36 1999 19 22
28. R. Hoffman, L.J. Murrav, J.C. Young, K.M. Luens, and E. Bruno Hierarchical structure of human megakaryocyte progenitor cells Stem Cells 14 suppl 1996 75 81
29. W.J. Lane, K. Hattori, and S. Dias Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation Exp Hematol 29 2001 1417 1424
30. E.C. Storen, and A. Tefferi Long-term use of anagrelide in young patients with essential thrombocythemia Blood 97 2001 863 866
31. M. Kobayashi, J.H. Laver, T. Kato, H. Miyazaki, and M. Ogawa Recombinant human thrombopoietin (Mpl ligand) enhances proliferation of erythroid progenitors Blood 86 1995 2494 2499
32. H. Minamiguchi, T. Kimura, and Y. Urata Simultaneous signalling through c-mpl, c-kit and CXCR4 enhances the proliferation and differentiation of human megakaryocyte progenitors: possible roles of the PI3-K, PKC and MAPK pathways Br J Haematol 115 2001 175 185